A missense GLP1R variant (rs10305492) associated with T2D and fasting glucose was used in secondary analyses
This suggests that semaglutides cardioprotective mechanisms extend beyond weight reduction, potentially involving anti-inflammatory effects, improvements in endothelial function, blood pressure, and lipid modulation, or direct vascular and central nervous system pathways, although these mechanisms were not directly tested in this analysis
The nerve cell loses its ability to produce ATP
This condition can lead to chronic nausea and vomiting, severe abdominal pain, malnutrition and dehydration, need for feeding tubes or surgical intervention, and permanent digestive complications
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide act on appetite signaling, satiety, and gastric emptying
Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results
